https://www.selleckchem.com/products/YM155.html
Significantly elevated CBVa was evident in premanifest zQ175 mice prior to motor deficits and striatal atrophy, recapitulating altered CBVa in human premanifest Huntington's disease. CRISPR/Cas9-mediated nonallele-specific HTT silencing in striatal neurons restored altered CBVa in premanifest zQ175 mice, delayed onset of striatal atrophy, and slowed the progression of motor phenotype and brain pathology. This study for the first time shows that a noninvasive functional MRI measure detects therapeutic efficacy in the premanifest stage and
Like
Comment
Share
